LW
Therapeutic Areas
BeiGene Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BRUKINSA (zanubrutinib) | Various B-cell malignancies (CLL, MCL, WM, MZL, FL) | Approved / Phase 3 |
| Tislelizumab | Various solid tumors (NSCLC, ESCC, GC, HCC, etc.) | Approved / Phase 3 |
| Ociperlimab (BGB-A1217) | Non-Small Cell Lung Cancer (1L) | Phase 3 |
| BGB-11417 (BCL-2 inhibitor) | Hematologic malignancies | Phase 2 |
| BGB-10188 (PI3Kδ inhibitor) | Hematologic malignancies & solid tumors | Phase 2 |